Global Metal Stent Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Metal Stent Market Analysis

The Metal Stent market is undergoing significant transformations, driven by evolving regulations, advancements in technology, and increasing healthcare demands. Recent innovations include the introduction of drug-eluting stents (DES) that release medication to prevent restenosis, significantly improving patient outcomes. For instance, Abbott's XIENCE Sierra stent, launched in India in May 2024, has been designed to enhance delivery and reduce the risk of complications. Additionally, the market is witnessing a shift towards bioresorbable stents, which dissolve over time, reducing long-term risks associated with permanent implants. In July 2024, MicroPort Scientific Corporation's Firesorb received market approval as the first fully bioresorbable cardiac stent, showcasing the industry's move toward safer alternatives. Moreover, regulatory bodies such as the FDA continue to approve new devices, ensuring that healthcare providers have access to the latest technologies. As cardiovascular diseases rise globally, the demand for innovative stenting solutions is expected to increase, positioning the metal stent market for robust growth in the coming years, fueled by ongoing research and improved patient care strategies.

Metal Stent Market Size

The global metal stent market size was valued at USD 6.44 billion in 2024 and is projected to reach USD 11.16 billion by 2032, with a CAGR of 7.10% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Metal Stent Market Trends

“Increasing Adoption of Bioresorbable Stents”

One prominent trend in the metal stent market is the increasing adoption of bioresorbable stents, which are designed to dissolve gradually in the body over time. Unlike traditional metal stents, which remain permanently in place, bioresorbable stents provide temporary support to the blood vessel, allowing it to regain its natural function without the long-term presence of a foreign object. This innovative approach addresses concerns related to late stent thrombosis and in-stent restenosis. For instance, recent advancements in bioresorbable technology have led to the development of stents such as the Absorb bioresorbable vascular scaffold, which has demonstrated promising outcomes in clinical trials. As healthcare providers and patients seek more effective and less invasive treatment options, the metal stent market is expected to witness significant growth driven by this trend toward bioresorbable alternatives, enhancing patient safety and satisfaction in cardiovascular interventions.

Report Scope and Metal Stent Market Segmentation

Metal Stent Market Definition

A metal stent is a small, tube-like device made of metal that is used to treat narrowed or blocked blood vessels or other tubular structures in the body. It is commonly utilized in procedures to alleviate conditions such as coronary artery disease, peripheral artery disease, and other vascular disorders. The stent is inserted into the affected area, typically using a minimally invasive technique known as angioplasty, where it is expanded to keep the vessel open, allowing for improved blood flow. Metal stents can be either bare metal or coated with medications (drug-eluting stents) that help prevent the re-narrowing of the vessel. Their design and materials aim to ensure biocompatibility and reduce the risk of complications, making them a crucial component in modern interventional cardiology and vascular surgery.

Metal Stent Market Dynamics

Drivers

• Increasing Incidence of Cardiovascular Diseases

The increasing incidence of cardiovascular diseases significantly propels the demand for effective stenting solutions, as these conditions are among the leading causes of morbidity and mortality worldwide. According to the World Health Organization, cardiovascular diseases account for approximately 32% of all deaths globally, with coronary artery disease and peripheral vascular disease being particularly prevalent. For instance, the American Heart Association reports that nearly 18.2 million adults in the U.S. have coronary artery disease, underscoring the urgent need for interventions such as stenting. As healthcare providers seek effective methods to manage these conditions, the demand for advanced stenting technologies, including drug-eluting and bioresorbable stents, continues to rise. This growing prevalence drives innovation in stent design and delivery systems but also expands the market as more patients undergo procedures requiring stent placements, positioning the metal stent market for robust growth in response to this critical health challenge.

• Growing Awareness of Cardiovascular Health

Growing awareness of cardiovascular health, coupled with improved access to healthcare services, is significantly contributing to higher diagnosis and treatment rates, which in turn boosts the metal stent market. As public health campaigns and educational programs emphasize the importance of cardiovascular health, individuals are becoming more proactive in seeking medical advice and undergoing routine screenings. For instance, the American Heart Association has reported that awareness initiatives have led to a 30% increase in the number of individuals getting checked for hypertension and high cholesterol, both of which are critical risk factors for cardiovascular diseases. Furthermore, the expansion of healthcare infrastructure and insurance coverage in many regions, particularly in developing countries, facilitates access to necessary medical treatments. With more patients diagnosed with cardiovascular conditions, there is a corresponding rise in the demand for effective treatments, including metal stents, thereby driving market growth. Enhanced access to healthcare services ensures that more patients can receive timely interventions, further solidifying the role of metal stents in the management of cardiovascular diseases.

Opportunities

• Increasing Advancements in Stent Technology

Advancements in stent technology represent a significant market opportunity, as continuous innovations in metal stent design, including drug-eluting and bioresorbable stents, are enhancing their effectiveness and improving patient outcomes. Drug-eluting stents, for instance, have been developed to release medication that helps prevent the re-narrowing of arteries, a condition known as restenosis. Studies show that these stents can reduce the risk of restenosis by up to 70% compared to bare metal stents, leading to better long-term results for patients. Additionally, the introduction of bioresorbable stents, which dissolve over time and eliminate the need for a permanent implant, is changing the landscape of cardiovascular treatment. For instance, the FDA-approved Absorb stent has demonstrated promising results in clinical trials, showing comparable efficacy to traditional stents while minimizing the long-term risks associated with foreign objects in the body. As healthcare providers seek to improve patient care and outcomes, these advancements in stent technology are driving demand but also expanding the market for innovative cardiovascular solutions, positioning manufacturers at the forefront of the evolving medical landscape.

• Rising Global Healthcare Expenditure

Rising healthcare expenditure globally presents a notable market opportunity for the metal stent market, as increased spending facilitates the adoption of advanced medical devices in hospitals and surgical centers. For instance, countries such as the United States are projected to spend over USD 4 trillion on healthcare by 2024, emphasizing the importance of investment in innovative medical technologies to improve patient outcomes. This financial commitment enables healthcare providers to procure devices, such as drug-eluting stents and bioresorbable stents, which offer significant benefits over traditional stents. As hospitals strive to enhance their treatment capabilities and provide quality care, the growing budget allows for the integration of advanced technologies that can lead to better procedural success rates and reduced complications. Furthermore, regions such as Asia-Pacific are also witnessing increased healthcare budgets, with countries such as China significantly expanding their healthcare infrastructure to support the rising demand for cardiovascular treatments. This trend underscores the significant potential for manufacturers in the metal stent market to capitalize on the growing investment in healthcare, driving innovation and improving patient care across diverse settings.

Restraints/Challenges

• Escalating Costs of Healthcare and Medical Devices

Cost constraints pose a significant challenge in the metal stent market, as the escalating costs of healthcare and medical devices compel hospitals and healthcare providers to search for more cost-effective solutions. This trend is particularly pronounced in price-sensitive markets where limited budgets restrict the procurement of advanced medical technologies. For instance, in emerging economies, healthcare facilities may prioritize lower-cost options, resulting in decreased demand for premium metal stents that offer enhanced features or performance. Manufacturers are thus faced with the dual challenge of maintaining high-quality standards while also managing production costs to offer competitive pricing. Additionally, as hospitals increasingly focus on cost containment and value-based care, the pressure to justify the expense of metal stents against their clinical benefits becomes more intense. This need for affordability can hinder the adoption of innovative stent technologies, making it crucial for manufacturers to develop strategies that balance quality, effectiveness, and cost to remain viable in the competitive landscape.

• Complex Regulatory Frameworks

Regulatory hurdles represent a significant challenge in the metal stent market, as manufacturers must adhere to stringent regulatory requirements that vary across different regions. The complexity of these regulations can result in lengthy and costly approval processes, delaying the introduction of new products to the market. For instance, in the United States, the Food and Drug Administration (FDA) requires extensive clinical data to demonstrate the safety and efficacy of stents before granting approval, a process that can take several years. This rigorous scrutiny can be particularly burdensome for smaller firms with limited resources, as they may struggle to meet the financial and logistical demands of compliance. Additionally, navigating varying regulations in global markets, such as those set by the European Medicines Agency (EMA) or Health Canada, can further complicate efforts to achieve market entry. As a result, these regulatory challenges can hinder innovation and slow the growth of the metal stent market, impacting the availability of new and improved stent technologies for patients.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Metal Stent Market Scope

The market is segmented on the basis of product type, technology, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Coronary Stents
• Peripheral Vascular Stents

Technology

• Bare Metal
• Drug Eluting
• Bioreabsorbable

End User

• Hospitals
• Ambulatory Surgical Centres
• Others

Metal Stent Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, technology, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the metal stents market, both in market share and revenue, and is expected to maintain this strong position throughout the forecast period. This dominance is driven by a surge in funding for research and development initiatives aimed at advancing stent technology, alongside a rising prevalence of cardiovascular disorders. The region's robust healthcare infrastructure and increased investment in innovative medical solutions further contribute to the growth of the metal stents market. As healthcare providers seek to enhance patient outcomes through improved stent designs and performance, North America remains a critical hub for advancements in this field.

Asia-Pacific is anticipated to experience the highest growth rate during the forecast period, driven by an increase in the consumption of unhealthy foods coupled with a rise in personal disposable income. As urbanization continues to expand and lifestyles become more fast-paced, the demand for convenience foods has surged, leading to higher incidences of lifestyle-related health issues. This, combined with growing economic prosperity, allows consumers greater access to healthcare services and stent technologies. Consequently, the region is set to witness significant advancements in medical interventions, particularly in the metal stents market, as healthcare systems adapt to the changing dietary habits and health needs of the population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Metal Stent Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Metal Stent Market Leaders Operating in the Market Are:

• Medtronic (U.S.)
• Abbott (U.S.)
• Boston Scientific Corporation (U.S.)
• Biotronik (Germany)
• B. Braun SE (Germany)
• Terumo Corporation (Japan)
• STENTYS SA (France)
• MicroPort Scientific Corporation (China)
• Meril Life Sciences Pvt. Ltd. (India)
• Vascular Concepts Ltd (U.K.)
• W. L. Gore & Associates, Inc. (U.S.)
• BD (U.S.)
• Endologix LLC (U.S.)
• Translumina (Germany)
• Artivion, Inc. (U.S.)
• Lombard Medical (U.K.)
• XCELL MEDICAL GROUP (U.S.)
• Cardinal Health (U.S.)
• Cook (U.S.)
• Drägerwerk AG & Co. KGaA (Germany)

Latest Developments in Metal Stent Market

• In September 2024, Translumina Therapeutics, a prominent coronary stent provider, announced the launch of its operations in the UAE. This move follows their collaboration with the esteemed German Heart Centre to develop advanced drug-eluting stent technologies, including the most extensively studied DES globally, backed by over a decade of research on safety and efficacy
• In July 2024, MicroPort Scientific Corporation revealed that its subsidiary, Shanghai MicroPort Medical (Group) Co., Ltd., obtained market approval from the NMPA for Firesorb, the first next-generation fully bioresorbable cardiac stent. Pre-market studies indicated that Firesorb demonstrated performance comparable to that of permanent drug-eluting stents in key clinical metrics, such as success rates and late lumen loss
• In May 2024, Global healthcare leader Abbott announced the introduction of the XIENCE Sierra, an everolimus-eluting coronary stent system, in India. This launch followed the system's regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) in February of the same year
• In May 2022, Medtronic plc, a global frontrunner in healthcare technology, announced that it received approval from the U.S. Food and Drug Administration (FDA) for the Onyx Frontier drug-eluting stent (DES). This stent represents the latest advancement in the Resolute DES family, utilizing the same best-in-class platform as the Resolute Onyx DES, but with an improved delivery system designed to enhance deliverability and performance in challenging cases
• In October 2021, The InspireMD CGuard Embolic Prevention Stent System (EPS) received reimbursement approval in France from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS) for the treatment of carotid artery disease (CAD) and stroke prevention

SKU-50329